BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

1:14 PM
Jan 23, 2018
 |  BC Innovations  |  Distillery Therapeutics


INDICATION: Solid tumors

Cell culture and mouse studies suggest combining Votrient pazopanib and a potassium channel inhibitor could help treat rhabdoid tumors. High throughput screening of a library of approved drugs in six human rhabdoid tumor cell lines and one human medulloblastoma cell line with the rhabdoid tumor marker SMARCB1 knocked out, identified the broad-spectrum tyrosine kinase...

Read the full 263 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >